Company intelligence / Profile preview

ImmuneBridge

San Francisco, California, United Statesimmunebridge.com ↗

Ownership: Private
Employees: ~26
Development stage: Preclinical

Overview

ImmuneBridge has demonstrated preclinical proof-of-concept for its platform by expanding cord blood-derived NK cells and aims to validate economic and clinical benefits in upcoming trials. The company recently raised $12M in seed funding to build screening datasets and generate preclinical data for its lead product targeting hematologic cancers. No clinical trial results have been published yet.

Therapeutic areas: Oncology
Modalities: Allogeneic cell therapiesnatural killer (NK) cellsimmune stem cells (hematopoietic stem/progenitor cells from cord blood)
Industry: Biotech

Beyond the preview

Go deeper on ImmuneBridge.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmuneBridge.